All In Biotech

Drug Trial Radar · NCT06943872

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 630 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

630

Planned (sponsor's estimate)

Start

Jun 11, 2025

Primary completion

Sep 30, 2029

Study completion Dec 2031

Sponsor

Lead sponsor
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
Sponsor type
Industry
Collaborators
German CLL Study Group
First posted
Apr 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The study will also compare how well sonrotoclax plus rituximab works versus venetoclax plus rituxumab in treating adults with R/R CLL/SLL. The safety of these treatments will also be assessed.

Conditions

  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma

Interventions

  • SonrotoclaxDrug

    Administered orally

  • ObinutuzumabDrug

    Administered intravenously

  • RituximabDrug

    Administered intravenously

  • VenetoclaxDrug

    Administered Orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) as assessed by Blinded Independent Review Committee (BIRC) for Arm A versus Arm DTime frame: Up to approximately 51 months

Locations

195 sites in 21 countries. Site status is shown where the registry gives one.

  • Uci Health Laguna Hills

    Laguna Hills, California · Recruiting

  • Chao Family Comprehensive Cancer Center

    Orange, California · Recruiting

  • Stanford Cancer Institute

    Palo Alto, California · Recruiting

  • Scripps Prebys Cancer Center

    San Diego, California · Recruiting

  • Rocky Mountain Cancer Centers (Williams) Usor

    Aurora, Colorado · Recruiting

  • Yale University Yale Cancer Center

    New Haven, Connecticut · Recruiting

  • Eastern Connecticut Hematology and Oncology

    Norwich, Connecticut · Recruiting

  • Cleveland Clinic Florida

    Weston, Florida · Recruiting

  • Northwestern University

    Chicago, Illinois · Recruiting

  • Illinois Cancer Specialists (Niles) Usor

    Niles, Illinois · Recruiting

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa · Recruiting

  • Mission Cancer and Blood

    Waukee, Iowa · Recruiting

  • University of Louisville, Brown Cancer Center

    Louisville, Kentucky · Recruiting

  • Mary Bird Perkins Cancer Center

    Baton Rouge, Louisiana · Recruiting

  • The University of Maryland Greenebaum Comprehensive Cancer Center

    Baltimore, Maryland · Recruiting

  • Beth Israel Deaconess Medical Center (Bidmc)

    Boston, Massachusetts · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • The Cancer and Hematology Centers

    Grand Rapids, Michigan · Recruiting

  • Mayo Clinic Rochester

    Rochester, Minnesota · Recruiting

  • University of Nebraska Medical Center

    Omaha, Nebraska · Recruiting

  • Sidney Kimmel Comprehensive Cancer Center Washington Twp

    Sewell, New Jersey · Recruiting

  • Christus St Vincent Regional Cancer Center

    Santa Fe, New Mexico · Recruiting

  • Memorial Sloan Kettering Cancer Center Mskcc

    New York, New York · Recruiting

  • Optum Medical Care, Pc

    Westbury, New York · Recruiting

  • University of North Carolina At Chapel Hill

    Chapel Hill, North Carolina · Recruiting

  • Levine Cancer Center

    Charlotte, North Carolina · Recruiting

  • Atrium Health Wake Forest Baptist

    Winston-Salem, North Carolina · Recruiting

  • Oncology Hematology Care Clinical Trials, Llc

    Cincinnati, Ohio · Recruiting

  • Oncology Associates of Oregon Willamette Valley Cancer Center

    Eugene, Oregon · Recruiting

  • Penn State Milton S Hershey Medical Center

    Hershey, Pennsylvania · Recruiting

  • Thomas Jefferson University

    Philadelphia, Pennsylvania · Recruiting

  • Upmc Hillman Cancer Center(Univ of Pittsburgh)

    Pittsburgh, Pennsylvania · Recruiting

  • Tennessee Oncology Greco Hainsworth Centers For Research Chattanooga

    Chattanooga, Tennessee · Recruiting

  • Tennessee Oncology

    Nashville, Tennessee · Recruiting

  • Texas Oncology Baylor Charles A Sammons Cancer Center

    Dallas, Texas · Recruiting

  • Texas Oncology San Antonio Medical Center Usor

    San Antonio, Texas · Recruiting

  • Texas Oncology Tyler

    Tyler, Texas · Recruiting

  • Swedish Medical Center Swedish Cancer Institute First Hill Campus

    Seattle, Washington · Recruiting

  • Northwest Cancer Specialist, Pc(Us Oncology Research)

    Vancouver, Washington · Recruiting

  • Hospital Aleman

    Caba, Argentina · Recruiting

Showing 40 of 195 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.